MeSH term
Frequency | Condition_Probility | Female | 202 | 0.0 |
Humans | 410 | 0.0 |
Pregnancy | 11 | 0.0 |
Adult | 159 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 7 | 1.0 |
Cisplatin/administration & dosage | 7 | 3.0 |
Drug Interactions | 4 | 0.0 |
Middle Aged | 138 | 0.0 |
Paclitaxel/administration & dosage | 2 | 7.0 |
Cysteine Endopeptidases/*blood | 3 | 60.0 |
*Neoplasm Proteins | 10 | 1.0 |
Research Support, Non-U.S. Gov't | 179 | 0.0 |
Disease Progression | 2 | 0.0 |
Down-Regulation | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Ceruloplasmin/*deficiency | 2 | 100.0 |
Electrophoresis, Gel, Two-Dimensional | 4 | 1.0 |
Lipid Peroxidation | 3 | 2.0 |
Mutation | 6 | 0.0 |
*Oxidative Stress | 3 | 1.0 |
Peptide Fragments/analysis | 2 | 0.0 |
Amino Acid Sequence | 20 | 0.0 |
Carbohydrate Sequence | 3 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
Molecular Sequence Data | 33 | 0.0 |
Sequence Homology | 2 | 0.0 |
Age Distribution | 2 | 0.0 |
Aged | 79 | 0.0 |
Aged, 80 and over | 24 | 0.0 |
Biological Markers/blood | 5 | 0.0 |
Chlamydophila pneumoniae/*immunology | 3 | 16.0 |
Cross-Sectional Studies | 2 | 0.0 |
Italy/epidemiology | 2 | 0.0 |
Male | 197 | 0.0 |
Risk Factors | 10 | 0.0 |
Seroepidemiologic Studies | 3 | 2.0 |
Sex Distribution | 2 | 0.0 |
Adolescent | 52 | 0.0 |
Animals | 91 | 0.0 |
*Antigens, Helminth | 2 | 50.0 |
Chickens | 4 | 0.0 |
Complement 3/metabolism | 4 | 1.0 |
*Helminth Proteins | 2 | 28.0 |
Hydrolysis | 4 | 0.0 |
Mice | 36 | 0.0 |
Oxidation-Reduction | 8 | 0.0 |
Sequence Alignment | 5 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Species Specificity | 4 | 0.0 |
Cysteine Endopeptidases/*chemistry | 2 | 50.0 |
Factor X/metabolism | 2 | 3.0 |
Rabbits | 11 | 0.0 |
Models, Biological | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 63 | 0.0 |
Edetic Acid | 2 | 4.0 |
Enzyme Activation | 5 | 0.0 |
Child | 38 | 0.0 |
Child, Preschool | 28 | 0.0 |
Comparative Study | 62 | 0.0 |
Infant | 17 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
Prospective Studies | 11 | 0.0 |
Recurrence | 3 | 0.0 |
Survival Analysis | 7 | 0.0 |
*Complement Pathway, Classical | 4 | 4.0 |
Cytotoxicity, Immunologic | 2 | 0.0 |
Kinetics | 19 | 0.0 |
Phagocytosis | 4 | 1.0 |
Protein Binding | 8 | 0.0 |
COS Cells | 2 | 0.0 |
Cell Line | 25 | 0.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Ceruloplasmin/deficiency/*genetics | 2 | 100.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Mice, Knockout | 3 | 0.0 |
Ceruloplasmin/*metabolism | 21 | 77.0 |
Copper/blood | 6 | 26.0 |
Homozygote | 3 | 0.0 |
Iron/blood | 2 | 2.0 |
Sex Factors | 7 | 0.0 |
Transferrin/metabolism | 3 | 1.0 |
Biomechanics | 2 | 1.0 |
English Abstract | 67 | 0.0 |
Time Factors | 30 | 0.0 |
Copper/*blood | 5 | 38.0 |
Oxidoreductases/*metabolism | 2 | 4.0 |
Oxygen/*metabolism | 2 | 1.0 |
Zinc/*blood | 3 | 12.0 |
Chronic Disease | 19 | 1.0 |
Data Interpretation, Statistical | 2 | 0.0 |
*Electrocardiography | 2 | 3.0 |
Predictive Value of Tests | 6 | 0.0 |
Retrospective Studies | 7 | 0.0 |
Sensitivity and Specificity | 5 | 0.0 |
Radioimmunoassay | 3 | 0.0 |
Neoplasm Proteins/*blood | 3 | 5.0 |
Neoplasm Staging | 4 | 0.0 |
Ceruloplasmin/genetics | 2 | 50.0 |
In Situ Hybridization | 4 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Trans-Activators/*genetics | 2 | 0.0 |
Transfection | 11 | 0.0 |
Immunohistochemistry | 13 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
Glutathione Peroxidase/blood | 3 | 8.0 |
Malondialdehyde/blood | 7 | 10.0 |
Statistics | 3 | 0.0 |
*Protein Biosynthesis | 2 | 0.0 |
U937 Cells | 2 | 0.0 |
*Chlamydophila pneumoniae | 2 | 20.0 |
Logistic Models | 2 | 0.0 |
*Polymorphism, Genetic | 5 | 0.0 |
Fluorescent Dyes | 2 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Chlamydophila pneumoniae/*isolation & purification | 2 | 20.0 |
DNA, Viral/analysis | 2 | 0.0 |
Polymerase Chain Reaction | 8 | 0.0 |
Infant, Newborn | 8 | 0.0 |
Prevalence | 4 | 0.0 |
Severity of Illness Index | 6 | 0.0 |
Case-Control Studies | 13 | 0.0 |
Ceruloplasmin/*analysis | 11 | 68.0 |
Statistics, Nonparametric | 3 | 0.0 |
Protein Conformation | 6 | 0.0 |
Trypanosoma cruzi/*enzymology | 2 | 50.0 |
Copper/metabolism | 6 | 9.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Lipoproteins, LDL/*metabolism | 2 | 1.0 |
Solubility | 3 | 0.0 |
Reference Values | 11 | 0.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Antioxidants/*metabolism | 4 | 4.0 |
Ceruloplasmin/metabolism | 5 | 18.0 |
Clinical Trials | 6 | 0.0 |
Cells, Cultured | 10 | 0.0 |
Tumor Cells, Cultured | 9 | 0.0 |
Follow-Up Studies | 8 | 0.0 |
Serologic Tests | 3 | 3.0 |
Blood Glucose/*metabolism | 3 | 1.0 |
C-Peptide/blood | 5 | 2.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Glucose Tolerance Test | 4 | 0.0 |
Insulin/blood | 4 | 0.0 |
Triglycerides/blood | 2 | 0.0 |
Copper/blood/metabolism | 2 | 66.0 |
Molecular Weight | 6 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Antibodies, Bacterial/blood | 2 | 2.0 |
Burkitt Lymphoma | 2 | 2.0 |
Cell Line, Transformed | 5 | 0.0 |
DNA Methylation | 2 | 0.0 |
Gene Expression Regulation, Viral | 2 | 0.0 |
Herpesvirus 4, Human/*genetics/metabolism | 2 | 40.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Transcription, Genetic | 9 | 0.0 |
Incidence | 7 | 0.0 |
Prognosis | 13 | 0.0 |
Electron Spin Resonance Spectroscopy | 3 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 13 | 0.0 |
Immunoelectrophoresis | 3 | 1.0 |
Reactive Oxygen Species/metabolism | 2 | 0.0 |
Spectrophotometry, Ultraviolet | 2 | 1.0 |
Brain/metabolism | 2 | 0.0 |
Regional Blood Flow | 2 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 15 | 0.0 |
Magnetic Resonance Imaging | 3 | 0.0 |
Callithrix | 2 | 2.0 |
*Enhancer Elements (Genetics) | 2 | 0.0 |
Herpesvirus 4, Human/*genetics/physiology | 2 | 22.0 |
*Promoter Regions (Genetics) | 12 | 0.0 |
Aging/*blood | 2 | 2.0 |
Cholesterol/blood | 4 | 0.0 |
Ceruloplasmin/chemistry/*metabolism | 2 | 40.0 |
Lipoproteins, LDL/metabolism | 3 | 1.0 |
Binding Sites | 13 | 0.0 |
Immunoblotting | 9 | 0.0 |
*Nuclear Proteins | 2 | 0.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Genotype | 6 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Diabetes Mellitus, Type 2/blood/*drug therapy | 2 | 4.0 |
Lipid Peroxides/blood | 2 | 8.0 |
Treatment Outcome | 7 | 0.0 |
Blotting, Western | 6 | 0.0 |
Base Sequence | 20 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
Enhancer Elements (Genetics) | 2 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Exercise/*physiology | 5 | 1.0 |
Cisplatin/*pharmacology | 3 | 2.0 |
In Vitro | 17 | 0.0 |
Alanine Transaminase/blood | 2 | 1.0 |
Hepacivirus/*genetics | 3 | 12.0 |
Drug Therapy, Combination | 8 | 0.0 |
Immunoglobulin G/blood | 3 | 1.0 |
Superoxide Dismutase/*blood | 4 | 15.0 |
Blood Coagulation Factors/*analysis | 3 | 3.0 |
Breast Neoplasms/*blood | 2 | 4.0 |
Cysteine Endopeptidases/*analysis | 2 | 50.0 |
Enzyme-Linked Immunosorbent Assay | 11 | 0.0 |
Ceruloplasmin/analysis | 9 | 31.0 |
Copper/blood/deficiency | 2 | 100.0 |
Dose-Response Relationship, Drug | 10 | 0.0 |
Drug Administration Schedule | 5 | 0.0 |
Neoplasm Metastasis | 4 | 0.0 |
Cohort Studies | 3 | 0.0 |
Hela Cells | 3 | 0.0 |
Microscopy, Electron | 7 | 0.0 |
Vinblastine/administration & dosage/analogs & derivatives | 2 | 33.0 |
Particle Size | 2 | 0.0 |
Cattle | 4 | 0.0 |
Cyclophosphamide/administration & dosage | 5 | 2.0 |
Acetylcholinesterase/*blood | 2 | 3.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
C-Reactive Protein/analysis | 5 | 0.0 |
Diabetes Mellitus, Type 2/*blood | 2 | 1.0 |
Hemoglobin A, Glycosylated/analysis | 4 | 0.0 |
*Lipid Peroxidation | 2 | 4.0 |
Oxidative Stress | 3 | 0.0 |
Transferrin/*analysis | 2 | 9.0 |
Ceruloplasmin/*genetics | 5 | 83.0 |
Blotting, Northern | 7 | 0.0 |
Glutathione/metabolism | 2 | 0.0 |
Models, Chemical | 2 | 0.0 |
Complement Pathway, Classical/*drug effects | 2 | 11.0 |
Guinea Pigs | 4 | 0.0 |
Plants, Medicinal/*chemistry | 2 | 11.0 |
Rats | 17 | 0.0 |
Sheep | 5 | 0.0 |
Cell Division | 3 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Analysis of Variance | 5 | 0.0 |
Drug Combinations | 2 | 0.0 |
Substrate Specificity | 4 | 0.0 |
Cyclophosphamide/toxicity | 2 | 50.0 |
*DNA Damage | 2 | 0.0 |
Hydrogen Peroxide/toxicity | 2 | 8.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Blood Proteins/*analysis | 4 | 2.0 |
3T3 Cells | 2 | 0.0 |
Cerebrospinal Fluid/*physiology | 2 | 66.0 |
Hepatolenticular Degeneration/*blood/genetics | 3 | 100.0 |
Liver/pathology | 3 | 1.0 |
Pilot Projects | 2 | 0.0 |
*Coronary Artery Bypass | 2 | 2.0 |
Heart Arrest, Induced | 2 | 20.0 |
Adenosine Triphosphate/metabolism | 4 | 0.0 |
*Exercise/physiology | 2 | 66.0 |
Glycogen/*metabolism | 2 | 14.0 |
Heart Rate | 3 | 1.0 |
Phosphocreatine/metabolism | 4 | 23.0 |
Age Factors | 6 | 0.0 |
Body Weight | 5 | 0.0 |
Catalase/blood | 2 | 9.0 |
Superoxide Dismutase/blood | 4 | 9.0 |
Epirubicin/administration & dosage | 2 | 5.0 |
Italy | 2 | 0.0 |
Arthritis, Rheumatoid/*blood | 2 | 4.0 |
Erythrocytes/enzymology | 3 | 0.0 |
Glutathione/blood | 2 | 4.0 |
CHO Cells | 3 | 0.0 |
Hamsters | 5 | 0.0 |
Receptors, Thrombin/metabolism | 2 | 11.0 |
Biotransformation | 6 | 1.0 |
Antibody Formation | 2 | 0.0 |
Epitopes | 2 | 0.0 |
Combined Modality Therapy | 6 | 0.0 |
Superoxides/metabolism | 2 | 0.0 |
Cross-Over Studies | 3 | 0.0 |
Injections, Intravenous | 5 | 0.0 |
Cleft Lip/epidemiology/*genetics | 2 | 25.0 |
Cleft Palate/epidemiology/*genetics | 2 | 25.0 |
Linkage (Genetics) | 2 | 0.0 |
DNA/genetics | 3 | 0.0 |
Heterozygote | 3 | 0.0 |
Odds Ratio | 2 | 0.0 |
Phenotype | 8 | 0.0 |
Alleles | 5 | 0.0 |
European Continental Ancestry Group/genetics | 3 | 0.0 |
Gene Frequency | 9 | 0.0 |
Calcium/metabolism | 4 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Dimerization | 3 | 0.0 |
Protein C/metabolism | 2 | 2.0 |
Biopsy | 2 | 0.0 |
Exertion/*physiology | 2 | 3.0 |
Glycogen/metabolism | 3 | 6.0 |
Hydrogen-Ion Concentration | 8 | 0.0 |
Lactic Acid/metabolism | 2 | 7.0 |
Muscles/*metabolism | 3 | 4.0 |
Oxygen Consumption/physiology | 2 | 2.0 |
Biopsy, Needle | 3 | 0.0 |
Ceruloplasmin/*analysis/metabolism | 2 | 100.0 |
Double-Blind Method | 3 | 0.0 |
Epstein-Barr Virus Nuclear Antigens/*genetics | 3 | 50.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Point Mutation | 3 | 0.0 |
B-Lymphocytes/*virology | 2 | 14.0 |
Herpesvirus 4, Human/*genetics | 7 | 9.0 |
Recombination, Genetic | 2 | 0.0 |
*Replication Origin | 2 | 11.0 |
Sequence Deletion | 2 | 0.0 |
Plasmids | 4 | 0.0 |
Blood Glucose/analysis | 6 | 0.0 |
Erythrocytes/metabolism | 2 | 1.0 |
Liver/metabolism | 2 | 0.0 |
Receptors, Cell Surface/metabolism | 3 | 0.0 |
Histidine | 2 | 4.0 |
Models, Molecular | 3 | 0.0 |
Aging/*physiology | 2 | 0.0 |
Body Mass Index | 3 | 0.0 |
Insulin/*blood | 6 | 3.0 |
Liver/*metabolism | 4 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
*Gene Expression Regulation, Viral | 5 | 1.0 |
Administration, Oral | 4 | 0.0 |
Antibodies, Bacterial/*blood | 2 | 4.0 |
Epitopes/immunology | 2 | 0.0 |
Immune Sera/immunology | 2 | 1.0 |
DNA Primers | 3 | 0.0 |
Kidney | 2 | 0.0 |
Neutralization Tests | 2 | 0.0 |
Liver Function Tests | 2 | 1.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Microsomes/metabolism | 2 | 1.0 |
Autoradiography | 2 | 0.0 |
Catalysis | 2 | 0.0 |
Energy Metabolism | 2 | 1.0 |
Linear Models | 2 | 0.0 |
Oxygen Consumption | 6 | 2.0 |
Genetic Markers | 2 | 0.0 |
*Genetics, Population | 4 | 1.0 |
Polymorphism, Genetic | 6 | 0.0 |
Venezuela | 3 | 9.0 |
Haptoglobins/analysis | 3 | 10.0 |
Orosomucoid/analysis | 3 | 6.0 |
Smoking | 2 | 0.0 |
Haemophilus influenzae/*immunology | 2 | 8.0 |
Epstein-Barr Virus Nuclear Antigens | 7 | 16.0 |
Ovarian Neoplasms/*drug therapy | 2 | 10.0 |
Binding, Competitive | 4 | 0.0 |
Actins/*metabolism | 3 | 1.0 |
Microfilament Proteins/*metabolism | 2 | 3.0 |
*Bacterial Capsules | 2 | 100.0 |
Antigens, Viral/*genetics | 2 | 11.0 |
Antigens, Viral/genetics | 3 | 16.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Blood Glucose/metabolism | 4 | 0.0 |
C-Peptide/*blood | 6 | 16.0 |
Immunosuppression | 2 | 1.0 |
*Kidney Transplantation | 2 | 0.0 |
Immunodiffusion | 2 | 0.0 |
Oxidoreductases | 2 | 100.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Copper/*metabolism | 5 | 5.0 |
*Renal Dialysis | 4 | 0.0 |
Kidney/*metabolism | 2 | 1.0 |
Hepatitis C/*epidemiology | 2 | 66.0 |
Urban Health | 2 | 5.0 |
Cell Survival/drug effects | 2 | 0.0 |
Microscopy, Electron, Scanning | 4 | 1.0 |
Potassium/analysis | 2 | 11.0 |
Cell Adhesion | 2 | 0.0 |
Gene Expression | 3 | 0.0 |
Acute Disease | 10 | 0.0 |
Complement 4/metabolism | 2 | 2.0 |
Swine | 3 | 0.0 |
Blood Proteins/*genetics | 3 | 1.0 |
Erythrocytes/*enzymology | 2 | 0.0 |
*Genetic Markers | 2 | 0.0 |
Glucagon/*pharmacology | 3 | 27.0 |
Infusions, Intravenous | 4 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
Cysteine Endopeptidases/*metabolism | 3 | 1.0 |
Abdomen | 2 | 2.0 |
Pedigree | 3 | 0.0 |
Gastric Mucosa/*pathology | 2 | 8.0 |
Blood Proteins/metabolism | 2 | 0.0 |
Pancreatitis/*blood | 2 | 11.0 |
Proinsulin/*blood | 2 | 18.0 |
Hepatolenticular Degeneration/*metabolism | 2 | 40.0 |
Regression Analysis | 3 | 0.0 |
Physical Endurance/*physiology | 2 | 4.0 |
DNA/analysis | 2 | 0.0 |
Lens, Crystalline/*chemistry | 2 | 28.0 |
Acute-Phase Proteins/*metabolism | 2 | 3.0 |
Interleukin-6/blood | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
Calcium/pharmacology | 2 | 0.0 |
T-Lymphocytes/*immunology | 2 | 0.0 |
Candida albicans | 2 | 18.0 |
Microspheres | 2 | 1.0 |
Monocytes/*immunology | 2 | 0.0 |
Phagocytosis/immunology | 2 | 3.0 |
Oxygen/metabolism | 2 | 0.0 |
Oxygen Consumption/*physiology | 3 | 9.0 |
Calcium/*metabolism | 3 | 0.0 |
Liver Neoplasms/*metabolism | 2 | 2.0 |
*Complement Activation | 5 | 1.0 |
Complement Pathway, Alternative | 3 | 2.0 |
Complement Pathway, Classical | 2 | 1.0 |
*ADP Ribose Transferases | 2 | 2.0 |
Bacterial Vaccines/*immunology/toxicity | 2 | 100.0 |
Blood Bactericidal Activity | 2 | 2.0 |
Polysaccharides, Bacterial/*immunology | 2 | 8.0 |
Staphylococcus aureus/*immunology | 2 | 2.0 |
*Virulence Factors | 2 | 2.0 |
Transplantation, Homologous | 2 | 0.0 |
Cerebral Palsy/*epidemiology | 3 | 100.0 |
Down Syndrome/*epidemiology | 2 | 33.0 |
Mental Retardation/*epidemiology | 2 | 100.0 |
Movement Disorders/*epidemiology | 3 | 100.0 |
Tokyo/epidemiology | 3 | 50.0 |
Ceruloplasmin/*pharmacology | 3 | 75.0 |
Lactates/*blood | 2 | 9.0 |
Random Allocation | 5 | 1.0 |
Autoantigens/*analysis | 2 | 9.0 |
Basement Membrane/immunology | 2 | 3.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Pemphigoid, Benign Mucous Membrane/*immunology | 3 | 100.0 |
Skin/*immunology | 3 | 2.0 |
Doxorubicin/administration & dosage | 2 | 1.0 |
Methotrexate/therapeutic use | 2 | 3.0 |
Up-Regulation/drug effects | 2 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Electrophoresis | 2 | 0.0 |
Cathepsins/*metabolism | 2 | 12.0 |
Fatigue/physiopathology | 2 | 50.0 |
Lactates/blood | 2 | 2.0 |
Pulmonary Gas Exchange/physiology | 2 | 14.0 |
Isoenzymes | 2 | 1.0 |
DNA, Viral | 2 | 1.0 |
Herpesvirus 4, Human/*genetics/immunology | 2 | 22.0 |
*Receptors, Immunologic | 4 | 2.0 |
*Receptors, Peptide | 4 | 16.0 |
Karyotyping | 2 | 0.0 |
Complement Fixation Tests | 2 | 2.0 |
*Complement Pathway, Alternative | 2 | 1.0 |
Monocytes/drug effects/metabolism | 2 | 2.0 |
Free Radicals | 2 | 1.0 |
Hemolysis/*drug effects | 2 | 5.0 |
*Parenteral Nutrition, Total | 2 | 3.0 |
Exercise Test | 2 | 0.0 |
Erythrocytes/drug effects/*metabolism | 2 | 10.0 |
Cross-Linking Reagents | 3 | 0.0 |
Concanavalin A/pharmacology | 2 | 0.0 |
Mercuric Chloride/pharmacology | 2 | 15.0 |
Blood Group Antigens/*genetics | 3 | 2.0 |
*Gene Frequency | 4 | 0.0 |
Lymphocyte Activation | 3 | 0.0 |
Arm | 2 | 6.0 |
Hemolysis/drug effects | 2 | 3.0 |
Pyloric Antrum/microbiology | 2 | 50.0 |
Chromatography, Thin Layer | 2 | 1.0 |
Complement Activation/*drug effects | 2 | 2.0 |
Complement Pathway, Alternative/drug effects | 2 | 9.0 |
Indicators and Reagents | 3 | 1.0 |
Hemolysis | 2 | 0.0 |
Pemphigoid, Bullous/*immunology | 2 | 11.0 |
Skin Diseases, Vesiculobullous/*immunology | 2 | 9.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Cyclophosphamide/administration & dosage/adverse effects | 2 | 9.0 |
Doxorubicin/administration & dosage/adverse effects | 2 | 13.0 |
Dose-Response Relationship, Immunologic | 3 | 0.0 |
Rats, Inbred Strains | 2 | 0.0 |
C-Peptide/blood/*metabolism/urine | 2 | 100.0 |
Microbial Collagenase/*blood | 2 | 100.0 |
India | 2 | 0.0 |
*Variation (Genetics) | 3 | 0.0 |
Iron/*metabolism | 2 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Cysteine/metabolism | 2 | 2.0 |
Transferrin/analysis | 2 | 2.0 |
Transferrin/*genetics | 2 | 4.0 |
alpha 1-Antitrypsin/analysis | 3 | 3.0 |
alpha-Macroglobulins/analysis | 2 | 5.0 |
Alkylation | 3 | 4.0 |
Spectrophotometry | 2 | 1.0 |
Microsomes, Liver/*metabolism | 2 | 1.0 |
Hypoglycemic Agents/pharmacology | 2 | 6.0 |
Obesity/metabolism | 2 | 4.0 |
*Ethnic Groups | 3 | 2.0 |
*Alcohol Drinking | 2 | 8.0 |
Flushing/*etiology | 2 | 40.0 |
Propionibacterium acnes/*immunology | 3 | 37.0 |
*Exertion | 3 | 1.0 |
Protein Denaturation | 2 | 0.0 |
Chemistry | 2 | 0.0 |
Cyclophosphamide/*metabolism | 2 | 33.0 |
Biological Markers/analysis | 2 | 0.0 |
